In this response, Roy and colleagues explain the model’s rationale, noting that its overall objective was to provide a framework for future use.
To the Editor: The study by Roy and colleagues (June 2015) presented a model framework to estimate the costs of treatment for relapsed and/or refractory multiple myeloma. We believe the assumptions applied in the study, particularly those regarding duration of therapy, lead to erroneous conclusions.

Results 1 - 2 of 2
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • National Association of Specialty Pharmacy
  • Lynx CME